Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Authors: Strickler, John H, Cercek, Andrea, Siena, Salvatore, André, Thierry, Ng, Kimmie, Van Cutsem, Eric, Wu, Christina, Paulson, Andrew S, Hubbard, Joleen M, Coveler, Andrew L, Fountzilas, Christos, Kardosh, Adel, Kasi, Pashtoon M, Lenz, Heinz-Josef, Ciombor, Kristen K, Elez, Elena, Bajor, David L, Cremolini, Chiara, Sanchez, Federico, Stecher, Michael, Feng, Wentao, Bekaii-Saab, Tanios S

Source: Lancet oncology. 24(5):496-508

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100190948618.0x000001&indx=1&recIds=ETOCvdc_100190948618.0x000001

Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers

Authors: Arora, Mansi, Bogenberger, James M., Abdelrahman, Amro M., Yonkus, Jennifer, Alva‐Ruiz, Roberto, Leiting, Jennifer L., Chen, Xianfeng, Serrano Uson Junior, Pedro Luiz, Dumbauld, Chelsae R., Baker, Alexander T., Gamb, Scott I., Egan, Jan B., Zhou, Yumei, Nagalo, Bolni Marius, Meurice, Nathalie, Eskelinen, Eeva‐Liisa, Salomao, Marcela A., Kosiorek, Heidi E., Braggio, Esteban, Barrett, Michael T., Buetow, Kenneth H., Sonbol, Mohamad B., Mansfield, Aaron S., Roberts, Lewis R., Bekaii‐Saab, Tanios S., Ahn, Daniel H., Truty, Mark J., Borad, Mitesh J.

Source: Hepatology. 75(1):43-58

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100143331037.0x000001&indx=1&recIds=ETOCvdc_100143331037.0x000001

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape

Authors: Ciombor, Kristen K., Strickler, John H., Bekaii-Saab, Tanios S., Yaeger, Rona

Source: Journal of clinical oncology. 40(24):2706-2715

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100169107712.0x000001&indx=1&recIds=ETOCvdc_100169107712.0x000001

Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma

Authors: Ueberroth, Benjamin E., Jones, Jeremy C., Bekaii-Saab, Tanios S.

Source: In Pancreatology September 2022 22(6):741-748

Evaluating the clinical benefits of anti-cancer drugs approved by Food and Drug Administration for gastrointestinal neoplasms for the past two decades.

Authors: Jamal, Fares, Sahvan, Oudai, Bekaii-Saab, Tanios S., Sonbol, Mohamad Bassam

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p820-820, 47p

Clinical outcomes and molecular characteristics of patients with locoregional ampullary carcinoma.

Authors: Eslinger, Cody, Chang, Isabela, Fonseca, Rodrigo, Sahvan, Oudai, Yee, Claire I., Truman, Mia, McWilliams, Robert R., Babiker, Hani M., Pai, Rish, Wu, Christina, Ahn, Daniel H., Borad, Mitesh, Bekaii-Saab, Tanios S., Sonbol, Mohamad B.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p732-732, 121p

Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.

Authors: Jazieh, Khalid, Babiker, Hani M., Foster, Nathan R., Fruth, Briant, Carr, Ryan Michael, Alberts, Steven R, Conboy, Caitlin, Tran, Nguyen H., Hartgers, Mindy L., Halfdanarson, Thorvardur Ragnar, Starr, Jason S., Sonbol, Mohamad Bassam, Jones, Jeremy Clifton, Ahn, Daniel H., Kankeu Fonkoua, Lionel Aurelien, Wu, Christina, Pedersen, Katrina Sophia, Bekaii-Saab, Tanios S., McWilliams, Robert R.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p727-727, 121p

Genomic alterations as predictive biomarkers for cancer-associated thrombosis (CAT) in biliary tract cancer (BTC).

Authors: Pirozzi, Angelo, Hoyek, Celine, Zheng-Lin, Binbin, Okano, Naohiro, Abidoye, Oluseyi, Eslinger, Cody, Babiker, Hani M., Majeed, Umair, Tran, Nguyen H., Rimassa, Lorenza, Bekaii-Saab, Tanios S., Shah, Surbhi, Borad, Mitesh J.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p634-634, 132p

A global comparative study on real-world clinical and genomic differences in advanced biliary tract cancer.

Authors: Abidoye, Oluseyi, Hoyek, Celine, Zheng-Lin, Binbin, Kosiorek, Heidi E., Eslinger, Cody, Sonbol, Mohamad Bassam, Wu, Christina, Tran, Nguyen H., Babiker, Hani M., Yoshino, Takayuki, Ikeda, Masafumi, Morizane, Chigusa, Bando, Hideaki, Nakamura, Yoshiaki, Fujisawa, Takao, Shibuki, Taro, Ahn, Daniel H., Roberts, Lewis R., Borad, Mitesh J., Bekaii-Saab, Tanios S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p628-628, 132p

Real-world (RW) treatment patterns and clinical outcomes of patients treated with sequential regorafenib and trifluridine/tipiracil ± bevacizumab (BEV) for metastatic colorectal cancer (mCRC) in the United States (US) community oncology setting:...

Authors: Bekaii-Saab, Tanios S., Cosgrove, David, Sruti, Ila, Shi, Junxin, Dai, Wei, Patton, Gregory Alan, Appukkuttan, Sreevalsa, Hocum, Brian Thomas, Katta, Arvind, Earl, Jacob, Babajanyan, Svetlana, Barzi, Afsaneh

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p62-62, 307p

Clinical and genomic characteristics of hepatocellular carcinoma-cholangiocarcinoma: Insights from real-world data.

Authors: Abidoye, Oluseyi, Chang, Isabela, Hoyek, Celine, Pirozzi, Angelo, Okano, Naohiro, Zheng-Lin, Binbin, Kosiorek, Heidi E., Eslinger, Cody, Sonbol, Mohamad B., Ahn, Daniel H., Wu, Christina, Yoshino, Takayuki, Ikeda, Masafumi, Morizane, Chigusa, Bando, Hideaki, Nakamura, Yoshiaki, Fujisawa, Takao, Shibuki, Taro, Borad, Mitesh J., Bekaii-Saab, Tanios S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p556-556, 132p

Real-world impact of matched targeted therapy on survival in advanced biliary tract cancer: An international collaborative study.

Authors: Zheng-Lin, Binbin, Hoyek, Celine, Kosiorek, Heidi E., Abidoye, Oluseyi, Eslinger, Cody, Sonbol, Mohamad Bassam, Wu, Christina, Tran, Nguyen H., Babiker, Hani M., Roberts, Lewis R., Yoshino, Takayuki, Ikeda, Masafumi, Morizane, Chigusa, Bando, Hideaki, Nakamura, Yoshiaki, Fujisawa, Takao, Ahn, Daniel H., Borad, Mitesh J., Shibuki, Taro, Bekaii-Saab, Tanios S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p536-536, 132p

First line atezolizumab + bevacizumab (atezo/bev) or durvalumab ± tremelimumab (durva±treme) in unresectable hepatocellular carcinoma (HCC): A real world, multi-institutional retrospective cohort study.

Authors: Kournoutas, Ioannis, Marell, Paulina S, Peersen, Anina, Gupta, Garima, Akce, Mehmet, Yang, Ju Dong, Chen, Pin-Jung, Naleid, Nikolas, Mahipal, Amit, Sahai, Vaibhav, Thompson, Scott, Jin, Zhaohui, Venkatesh, Sudhakar, Borad, Mitesh J., Babiker, Hani M., Bekaii-Saab, Tanios S., McWilliams, Robert R., Halfdanarson, Thorvardur Ragnar, Ou, Fang-Shu, Tran, Nguyen H.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p532-532, 132p

Neoadjuvant immunotherapy and nonoperative management of dMMR gastroesophageal adenocarcinoma (GEA): A retrospective case series.

Authors: Sahvan, Oudai, Jamal, Fares, Borad, Mitesh J., Bekaii-Saab, Tanios S., Wu, Christina, Ahn, Daniel H., Sonbol, Mohamad Bassam

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p451-451, 188p

Acquired gene alterations potentially related to resistance to anti-HER2 therapy in HER2-positive metastatic colorectal cancer (mCRC).

Authors: Hoyek, Celine, Zheng-Lin, Binbin, Pirozzi, Angelo, Abidoye, Oluseyi, Eslinger, Cody, Iida, Naoko, Nakamura, Yoshiaki, Ramaker, Ryne, Sonbol, Mohamad Bassam, Wu, Christina, Borad, Mitesh J., Ahn, Daniel H., Ikeda, Masafumi, Shibuki, Taro, Yoshino, Takayuki, Strickler, John H, Bekaii-Saab, Tanios S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p277-277, 307p

Impact of baseline alterations in HER2-pathway oncogenic drivers on response to anti-HER2 therapy in patients (pts) with HER2-amplified advanced colorectal cancer (aCRC).

Authors: Hoyek, Celine, Pirozzi, Angelo, Zheng-Lin, Binbin, Abidoye, Oluseyi, Eslinger, Cody, Nakamura, Yoshiaki, Ramaker, Ryne, Sonbol, Mohamad Bassam, Wu, Christina, Borad, Mitesh J., Ahn, Daniel H., Ikeda, Masafumi, Shibuki, Taro, Yoshino, Takayuki, Strickler, John H, Bekaii-Saab, Tanios S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p243-243, 307p

Impact of education on clinical confidence utilizing HER2-targeted therapies in colorectal cancer.

Authors: Cohen-Solal, Karine, Ackbarali, Tariqa, Strickler, John H, Bekaii-Saab, Tanios S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p225-225, 307p

Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.

Authors: Hecht, Joel R, Davar, Diwakar, Fakih, Marwan, Bekaii-Saab, Tanios S., DeVito, Nicholas C., Knecht, John George, Vandross, Andrae Lavon, Perez, Cesar Augusto, Bessudo, Alberto, Gupta, Anurag, Patel, Ekta, Fantini, Damiano, Paramasivan, Sattanathan, Crowe, David, Duncan, Meghan, McConnell, Scott, Luptakova, Katarina, Parikh, Aparna Raj

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p206-206, 307p

Immunotherapy outcomes in dMMR/MSI-H and/or TMB-H metastatic colorectal cancer (CRC) with peritoneal metastases (PM).

Authors: Mosalem, Osama M, Elhariri, Ahmed, Wiest, Nathaniel Edward, Kamatham, Saivaishnavi, Abdel-Razeq, Nayef Hikmat, Jones, Jeremy Clifton, Sonbol, Mohamad B., Jin, Zhaohui, Babiker, Hani M., Bekaii-Saab, Tanios S., Majeed, Umair, Starr, Jason S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p163-163, 307p

Adagrasib (Ada) + cetuximab (Cetux) for KRAS G12C -mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.

Authors: Yaeger, Rona, Uboha, Nataliya V., Klempner, Samuel J., Bekaii-Saab, Tanios S., Sabari, Joshua K., Barve, Minal A., Saltzman, Joel N., Peguero, Julio Antonio, Paulson, Andrew Scott, Jänne, Pasi A., Pelster, Meredith, Cruz-Correa, Marcia, Kim, Amy Min Kyung, Hu, Nan, Ahmad, Harris A., Kopetz, Scott

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p131-131, 307p